

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

SIR 7645


In re Patent Application of

SHAW, D. et al.

Serial No. 10/088,341

Filed: March 18, 2002

Title: ORAL RECOMBINANT LACTOBACILLI VACCINES



Atty Dkt. 117-385

C# M#

T.C. / Art Unit: 1645

Examiner: S.J. Devi

Date: July 25, 2005

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

AMENDMENT UNDER 37 CFR § 1.111

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

 Correspondence Address Indication Form Attached.**Fees are attached as calculated below:**

Total effective claims after amendment	43	minus highest number previously paid for	32	(at least 20) =	11	x \$50.00	\$550.00 (1202)/\$275.00 (2202)	\$ 550.00
----------------------------------------	----	------------------------------------------	----	-----------------	----	-----------	---------------------------------	-----------

Independent claims after amendment	6	minus highest number previously paid for	6	(at least 3) =	0	x \$200.00	\$0.00 (1201)/\$0.00 (2201)	\$
------------------------------------	---	------------------------------------------	---	----------------	---	------------	-----------------------------	----

If proper multiple dependent claims now added for first time, (ignore improper); add	\$360.00 (1051)/\$180.00 (2051)	\$
--------------------------------------------------------------------------------------	---------------------------------	----

Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s)	One Month Extension \$120.00 (1251)/\$60.00 (2251)
-----------------------------------------------------------------------------------------------------------------------	----------------------------------------------------

Two Month Extensions \$450.00 (1252)/\$225.00 (2252)

Three Month Extensions \$1020.00 (1253)/\$510.00 (2253)

Four Month Extensions \$1590.00 (1254)/\$795.00 (2254)	\$ 120.00
--------------------------------------------------------	-----------

Terminal disclaimer enclosed, add	\$130.00 (1814)/ \$65.00 (2814)	\$
-----------------------------------	---------------------------------	----

<input type="checkbox"/> Applicant claims "small entity" status.	<input type="checkbox"/> Statement filed herewith
------------------------------------------------------------------	---------------------------------------------------

Rule 56 Information Disclosure Statement Filing Fee	\$180.00 (1806)	\$
-----------------------------------------------------	-----------------	----

Assignment Recording Fee	\$40.00 (8021)	\$
--------------------------	----------------	----


Other:		\$
--------	--	----

TOTAL FEE ENCLOSED	\$ 670.00
---------------------------	------------------

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

901 North Glebe Road, 11th Floor
Arlington, Virginia 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
GRT:ap

NIXON & VANDERHYE P.C.
By Atty: Gary R. Tanigawa, Reg. No. 43,180

Signature: 



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Confirmation No. 9257

SHAW et al.

Atty. Ref.: 117-385

Appln. No. 10/088,341

T.C. / Art Unit: 1645

Filed: June 25, 2002

Examiner: S.J. Devi

FOR: ORAL RECOMBINANT LACTOBACILLI VACCINES

* * *

AMENDMENT UNDER 37 CFR § 1.111

Monday, July 25, 2005

Mail Stop Amendment

Hon. Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In response to the pending Office Action mailed March 23, 2005, entry and consideration of the following amendments and remarks are respectfully requested.

An amended portion of the **specification** is presented on page 2.

The brief description of the figure is amended.

The **claims** are presented on pages 3-9.

Claims 1-7, 9, 12-13, 15-16, 18, 20-24 and 32 are amended.

Claims 11, 14 and 19 are canceled without prejudice or disclaimer.

Claims 33-46 are added.

Remarks begin on page 10.

07/26/2005 JADDO1 00000075 10088341

01 FC:1202
02 FC:1251

550.00 OP
120.00 OP

975621